# Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

> **NCT02780609** · PHASE1,PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 22 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Melphalan
- **DRUG:** Dexamethasone
- **PROCEDURE:** Autologous Hematopoietic Cell Transplantation (HCT)
- **DRUG:** Fosaprepitant

## Key facts

- **NCT ID:** NCT02780609
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-20
- **Primary completion:** 2021-02-20
- **Final completion:** 2021-02-23
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2022-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02780609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02780609, "Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02780609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*